Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
A Prospective, Single-arm Clinical Study on Re-irradiation Combined With Chidamide in the Treatment of Patients With Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy
West China Hospital
6 participants
Apr 23, 2026
INTERVENTIONAL
Conditions
Summary
To evaluate the safety and tolerability of re-irradiation combined with chidamide in patients with recurrent head and neck squamous cell carcinoma after radiotherapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dose Escalation Design: Chidamide will be administered orally according to the protocol-specified schedule(20mg BIW). Administration Schedule: Chidamide treatment initiates 1 week prior to the start of re-irradiation(to achieve steady-state plasma concentration). The interval between doses is no less than 3 days. Administration time is 30 minutes after breakfast, continuing until the completion of radiotherapy.
Dose Escalation Design: Chidamide will be administered orally according to the protocol-specified schedule(30mg BIW). Administration Schedule: Chidamide treatment initiates 1 week prior to the start of re-irradiation(to achieve steady-state plasma concentration). The interval between doses is no less than 3 days. Administration time is 30 minutes after breakfast, continuing until the completion of radiotherapy.
All subjects receive fixed-dose Intensity-Modulated Radiation Therapy (IMRT): 60 Gy in 30 fractions (2 Gy per fraction), administered once daily, 5 days a week.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07545967